KNSA — Kiniksa Pharmaceuticals International Share News
0.000.00%
Last trade - 00:00- $6.24bn
- $5.71bn
- $677.56m
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Nucor, Copper miners
Kiniksa hits over 2-year high on upbeat Arcalyst sales outlook
Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in June - Earnings Summary
Brief: Kiniksa Pharmaceuticals Q2 EPS USD 0.21
Kiniksa Pharmaceuticals Ltd expected to post a loss of 17 cents a share - Earnings Preview
Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in March - Earnings Summary
Brief: Kiniksa Pharmaceuticals Q1 EPS USD -0.18
Brief: Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results And Recent Portfolio Execution
Kiniksa Pharmaceuticals Ltd expected to post a loss of 21 cents a share - Earnings Preview
Brief: Kiniksa Pharmaceuticals Announces To Its Investors, It Did Not Have Exposure To Silicon Valley Bank
Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in December - Earnings Summary
Brief: Kiniksa Pharmaceuticals Reports Q4 And Full-Year 2022 Financial Results
Brief: Kiniksa Pharmaceuticals Posts Q4 Product Revenue USD 39.939 Million
Kiniksa Pharmaceuticals Ltd expected to post a loss of 23 cents a share - Earnings Preview
Brief: Kiniksa Pharmaceuticals Provides Corporate And Portfolio Update
Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in September - Earnings Summary
Brief: Kiniksa Pharmaceuticals Reports Q3 Results
Kiniksa Pharmaceuticals Ltd expected to post earnings of 50cents a share - Earnings Preview
Brief: Kiniksa Pharmaceuticals Announces Closing Of Global License Agreement With Genentech For Vixarelimab